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Abstract:  Non-invasive near-infrared fluorescence (NIRF) imaging is a 
powerful tool to study pathophysiology in a wide variety of animal disease 
models including brain diseases. However, especially in NIRF imaging of 
the brain or other deeper laying target sites, background fluorescence 
emitted from the scalp or superficial blood vessels can impede the detection 
of fluorescence in deeper tissue. Here, we introduce an effective method to 
reduce the impact of fluorescence from superficial layers. The approach 
uses excitation light at two different wavelengths generating two images 
with different depth sensitivities followed by an adapted subtraction 
algorithm. This technique leads to significant enhancement of the contrast 
and the detectability of fluorochromes located in deep tissue layers in tissue 
simulating phantoms and murine models with stroke. 
©2010 Optical Society of America 
OCIS codes: (0100.2980) Image Enhancement; (0110.2960) Imaging analysis. 
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Introduction 
A growing number of animal experimental studies show that non-invasive near-infrared 
fluorescence (NIRF) imaging can be successfully used for specific visualization of biological 
processes in a wide variety of animal disease models [1,2] including models for cancer [3], 
vascular disease [4] or arthritis [5]. The technique has also been applied for studying brain 
pathologies such as brain tumors [6–8], neurodegenerative diseases [9,10], or cerebral 
ischemia [11–13]. Various methodological challenges have to be considered when applying 
non-invasive NIRF imaging to animal models of brain disease or other deeper laying targets 
in general. Due to extinction in tissues, the number of excitation photons reaching a deep-
seated fluorescence site and the subsequent number of fluorescence photons reaching back the 
surface decreases nonlinearly with the depth of the fluorescent object of interest. NIRF epi-
illumination imaging is inherently highly sensitive to fluorescent sources in superficial layers. 
Thus, the non-invasive visualization of compound binding or uptake within deeper tissue 
mingles with strong superficial background signals [13,14]. In the particular case of planar 
fluorescence imaging of the murine head, these signals originate from large vessels on the 
dorsal surface of the brain [15] and the highly vascularized scalp, skull bone, and dura mater. 
Addressing this issue, we here describe and validate a technique to improve the contrast of 
non-invasive fluorescence images using the example of the murine brain by subtracting the 
contribution of unspecific fluorescence coming from superficial structures using two different 
excitation wavelengths, 670 nm and 633 nm. We have done Monte-Carlo simulations to 
mimic the depth-dependent sensitivity of different excitation wavelengths in an epi-
illumination NIRF imaging system and tested this ‘non-invasive surface-stripping’ approach 
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Theory 
In the wavelength range discussed here, blood is the most relevant absorber. At 633 nm the 
absorption coefficient of hemoglobin is a factor 2-5 higher than at 670 nm [16,17], thus the 
associated fluorescence image owns a stronger relative weight for the fluorescence from 
superficial layers than the fluorescence image obtained for an excitation at 670 nm. In a 
simplistic model, we can describe a deep laying fluorescing inclusion with a concentration 
c
deep, while fluorescent sources from superficial layers shall be represented by c
surf. At two 
different wavelengths the fluorescence detected in an epi-illumination fluorescence imaging 
system is 
  ( ) 633 1 633 633
fluo surf surf deep deep
nm nm nm I Sc Sc α =+  
  ( ) 670 2 670 670
fluo surf surf deep deep
nm nm nm I Sc Sc α =+    (1) 
fluo Iλ  is the measured fluorescence intensity per image voxel in J/cm
2s, 
surf Sλ and 
deep Sλ are 
the sensitivities for wavelength λi in J٠L/(cm
2s mol), α1 and α2 are coupling coefficients and 
c
surf, c
deep are the mean fluorophore concentrations in mol/L for the superficial layers and the 
inclusion depth, respectively. A difference image Î of both fluorescence images [Eq. (1)] can 
be defined, potentially reducing the influence of the superficial layers 
  670 633
fluo fluo
nm nm ÎI I β = −⋅    (2) 
When β is chosen β = (α2 670
surf
nm S )/(α1 633
surf
















.   (3) 
In Eq. (3) the difference image Î is no longer a function of c
surf but is now dependent only 
on the concentration of the inclusion c
deep and a proportionality constant α2. The latter could 
be determined using a calibration phantom with a known fluorochrome concentration. 
In practice, however, neither the sensitivities nor the coupling coefficients α1 or α2 are 
known, so a different way is needed to determine β. If prior knowledge of the fluorophore 
distribution  is  not  available,  β  can  be  defined  using  histogram  equalization  (HE)  of  both 
fluorescence images. Here we assume the inclusion to be focal and the major part of both 
image intensities to be similarly distributed. HE transforms the signal intensity of the entire 
image acquired at 633 nm excitation wavelength to the same order of magnitude of signal 
level as the 670 nm image. Thus the difference between the two images after HE is mainly 
due to the focal inclusion of an unknown position in the brain. A histogram equalized 
subtraction thus allows the determination of Î, which is a brain weighted fluorescence image 
where signal intensities coming from superficial layers are highly reduced as they contribute 
to both fluorescence images excited at 670 nm and 633 nm, respectively. 
Methods 
Monte Carlo Simulation 
To estimate the penetration depth at the two excitation wavelengths sensitivity factors were 
calculated with the help of a Monte Carlo simulation program developed by L.Wang and 
S.Jacques [18,19]. The simulation propagates photons in three dimensions and records photon 
deposition, A(x, y, z) in J/cm
3, due to absorption in each grid element of a spatial array. We 
calculated the responses to a finite 710 nm photon beam with a radius of 0.03 cm and two flat 
beam geometries at 633 nm and 670 nm, with a radius of 1.5 cm each, impinging on a slab, 
homogenous half space. Multiplying the latter two measures by the first mimics the spread 
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fluorescence light with a camera system. For every wavelength, we simulated 107 photons 
using a voxelsize of 0.006 cm
3, the anisotropy factor g was assumed to be 0.9 and the 
scattering coefficients µs633nm = 0.22 /mm, µs670nm = 0.20/mm and µs710nm = 0.18/mm were 
taken from [20]. The used absorption properties of µa633nm = 0.027/mm, µa670nm = 0.014/mm 
and µa710nm  = 0.0095/mm correspond to a total cerebral hemoglobin concentration of 
60µmol/L, with an oxygen saturation of 70%, dissolved in water based on the molar 
extinction coefficients published by Scott Prahl [17]. 
Fluorescence reflectance imaging 
NIRF imaging was performed using a system developed by our group whereby fluorescence 
epi-illumination images can be taken at different excitation wavelengths without moving the 
animal [14]. Light from two TE-cooled laser diodes emitting 670 nm and 633 nm (Roithner 
Lasertechnik, Vienna, Austria) was coupled to an optical switch (LightTech Fiberoptics Inc, 
San Leandro, CA) and directed into a dark chamber, where it illuminated the object from 
above. A back-illuminated nitrogen-cooled CCD camera (Vers Array 512, 512 x 512 px, 
Roper Scientific Inc., Duluth, GA) with a focusing lens system (Nikkor macro lens, f = 50 
mm, f/1.2, Nikon, Duesseldorf, Germany) and two 710-nm interference filters (FWHM 20 
nm, Andover Corp., Salem, NH) detected the emitted fluorescence light. 
Tissue phantom 
The first column of Fig. 2  sketches the measurement set-up for the tissue phantom. We 
embedded a 2 mm long translucent polyethylene capsule (outer diameter of 0.61 mm, inner 
diameter of 0.26 mm, net volume 0.1 ml, SIMS Portex Ltd, Kent, UK) containing 10
−12 mol of 
the fluorophore Cy5.5 (Cy5.5-dextran, Nanocs, New York, NY) beneath one or two layers of 
pork meat (4 mm each) with and without an additional top layer of fluorophore concentration 
(Cy5.5-dextran, Nanocs, New York, NY). 
In-vivo model with implanted fluorescent capsule 
In-vivo mouse model measurements were done with a mouse model described in detail in 
[14]. Translucent polyethylene tubes (outer diameter of 0.61 mm, inner diameter of 0.26 mm, 
SIMS Portex Ltd, Kent, UK) were filled with a Cy5.5-PEG solution (MW = 23 kDa, Nanocs, 
New York, NY). The tubes were cut into lengths of 2 mm and then thermally sealed 
containing a net volume of 0.1 ml and 10
−12 mol Cy5.5. 
An adult male C57Bl6 mouse weighing 25 g (Bundesinstitut fuer Risikoforschung, Berlin, 
Germany) was anaesthetized with a 5% solution of chloral hydrate (200 mg/kg) injected 
intraperitoneally. The hair was removed at the dorsal part of the head, the left temporalis 
muscle was detached, a hole was drilled into the skull and a capsule deposited at a depth of 
about 4 mm in the cortex of the left hemisphere approximately 2 mm caudal from bregma. 
The hole was closed using skin glue (Dermabond GmbH, Norderstedt, Germany) and muscle 
and skin were fixed into their original place. To simulate background fluorescence from 
fluorophores circulating in the vasculature, we injected 2 x 10
−10 mol Cy5.5-PEG through the 
tail vein after the first set of NIRF measurements. After the bolus injection, the fluorophore 
concentration in the blood was approximately 0.1 µmol/L assuming a total blood volume of 2 
mL in the mouse. The dye was allowed to equilibrate for 1 min before NIRF imaging   
[Fig. 3(a) and 3(b)]. 
In-vivo mouse model with stroke 
The surface-stripping approach was also tested in-vivo with male C57Bl6/N mice that had 
undergone middle cerebral artery occlusion performed as previously published [12,21]. A 
monofilament was introduced into the common carotid artery under isoflurane anesthesia, 
advanced to the origin of the middle cerebral artery, and left there for 30 min, until 
reperfusion. 
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387nm/mL, dissolved in 200µL NaCl, German Cancer Research Center Heidelberg) was 
injected intravenously 96 h after reperfusion. NIRF imaging was performed 2 h after injection 
of Cy5.5-albumin and the brain was then removed from the skull under deep anesthesia and 
used for ex vivo NIRF imaging [Fig. 4]. 
All procedures were in accordance with German animal welfare laws. 
Data processing and image analysis 
Data processing and analysis were performed using Matlab 6.5 software (The Mathworks, 
Inc., Natick, MA). An automatic baseline correction prior to analysis removed the read-out 
noise offset. All images were normalized to acquisition time and a top hat image (top hat 
filtering, structuring element circle with a diameter of 4 pixels) was subtracted from each 
image to correct for superficial fluorescence from dust. For illustration and comparison, all 
resulting fluorescence images were normalized to the maximum value of the fluorescence 
image, excited with 670 nm and smoothed by spatial filtering. 
The surface-stripping algorithm 
Before subtracting both fluorescence images excited with 633 nm and 670 nm, respectively, a 
histogram equalization (HE) was performed. The histogram of the fluorescence image I633nm 
was stretched in steps to find the factor βHIS that best minimizes the bounded area between the 
parametric representation of the histograms of I670nm and βHIS٠ I633nm. The difference (I670nm – 
βHIS٠ I633nm) was then calculated and negative pixel values of the adapted subtraction image 
were set at zero. 
Results 
 
Fig. 1. Monte-Carlo results. (a) Normalized sensitivity in a logarithmic scale as a function of 
depth for a point inclusion fluorescing at 710 nm, spread excitation beams at 633 nm and 670 
nm and a point-wise detection. This mimics the spread excitation of a fluorescent source in an 
epi-fluorescence imaging system and the detection with a camera system. (b) Quotient of the 
normalized sensitivities shown in (a). 
The Monte Carlo results demonstrate the decrease in photon sensitivity with increasing depth 
for a point inclusion fluorescing at 710 nm and a point-wise detection when excited with 
spread excitation beams at 633 nm and 670 nm [Fig. 1(a)] and illustrate the very high 
sensitivity of epi-fluorescence images for dye concentrations in superficial layers. The ratio of 
these normalized sensitivities shows that the difference in inclusion signal intensity, between 
both excitation wavelengths grows exponentially with depth [Fig. 1(b)]. At an inclusion depth 
of 0.5 cm the fluorescence image excited with 670 nm is about a factor 2 more sensitive than 
the corresponding image excited with 633 nm, considering the same number of fluorescence 
photons being released by both excitation wavelengths. 
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Fig. 2. Color-coded NIRF images of the tissue phantom study. Capsules containing NIRF dye 
Cy5.5 embedded in meat as sketched in a vertical view in the first column. Images with 
illumination at 670 (left) or 633 nm (middle), and the resulting depth-weighted images (right) 
are shown. The red circles indicate the position of the fluorescent target. (a) capsule located 4 
mm below the surface. (b) capsule located 8 mm below the surface. The asterisk indicates an 
area of strong superficial tissue autofluorescence, which is strongly reduced in the depth-
weighted image. (c) capsule located 8 mm below the surface and a dye solution is applied 
topically on the surface. The color bars represent relative fluorescence intensities (arbitrary 
units). 
Figure 2 shows NIRF images of a capsule containing 10
−12 mol of the NIR fluorochrome 
Cy5.5 in a tissue phantom. Three different experimental situations are sketched in the first 
column of the figure. In the first example [Fig. 2(a)], the capsule is covered by a 4 mm layer 
of pork meat. The capsule can be clearly seen in the raw fluorescence images excited with 670 
nm and 633 nm, respectively, as well as in the histogram equalized subtraction image (‘depth-
weighted’ image). In the second example [Fig. 2(b)], the inclusion is embedded in meat at a 
depth of 8 mm. Without prior knowledge, it cannot be univocally localized on either NIRF 
image. The detection of the fluorescent inclusion is further hampered by a superficial 
fluorescent signal in the upper right corner, as indicated by the asterisk. In the subtraction 
image, the unwanted superficial signals are strongly suppressed and the capsule can be clearly 
localized. When an NIRF dye solution is applied topically to increase the fluorescence at the 
very surface of the phantom [Fig. 2(c)], the 8 mm deep inclusion is only visible after the 
surface-stripping algorithm is applied. Notably, an improved contrast and a clear reduction of 
the effect of superficial layers can be observed in all cases. 
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Fig. 3. Non-invasive NIRF images of a live mouse implanted with an intracranial capsule 
containing 10
−12  mol Cy5.5-PEG. Images after illumination with light of 670 or 633 nm 
wavelengths, and the resulting depth-weighted images are depicted. (a) before and (b) after i.v.-
injection of 2 x 10
−10mol Cy5.5-PEG. 
Figure 3(a) and 3(b)  show fluorescence images of a living mouse with a surgically 
implanted fluorescent capsule located about 4 mm deep into the left hemisphere of the brain. 
Before application of a long-circulating dye [Fig. 3(a)], the implanted capsule is visible after 
excitation at either wavelength. Ubiquitous background tissue fluorescence is further depleted 
after applying the subtraction scheme. After intravenous injection of 2 x 10
−10 mol Cy5.5-PEG 
to increase background fluorescence [Fig. 3(b)], a mixed contribution from the capsule as well 
as from the confluens sinuum [confluence of superior sagittal and transverse venous sinuses] 
is observed. The latter cancels out almost completely after the ‘non-invasive surface-
stripping’ algorithm: the rather diffuse fluorescence signal of the raw images is focused and 
localized to the area overlying the implanted capsule. 
 
Fig. 4. Non-invasive NIRF images of a live mouse after experimentally  induced cerebral 
ischemia in the left hemisphere 2 h after i.v.-injection of NIRF-labeled albumin. 
Figure 4 demonstrates how the subtraction scheme facilitates the detection of a fluorescent 
compound accumulating in the diseased brain tissue in a mouse model of stroke. After 
experimentally inducing cerebral ischemia in a mouse, fluorescently labeled albumin, a 
marker for blood-brain barrier disruption, was injected intravenously. No detected 
fluorescence signal could be primarily attributed to the ischemic hemisphere at 670 or 633 nm 
excitation wavelengths, both images are dominated by the centered fluorescence signal from 
the confluens sinuum. After use of the technique presented in this paper, a focal NIRF signal 
emerged, which corresponds well with the location of the fluorescence over the ischemic area 
on the ex vivo image taken after removal of the skull. 
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Our new technique enables the visualization of fluorescent sources located deep in tissue 
layers where detection was previously hampered by strong fluorescence from superficial 
structures. In all experimental settings investigated, the application of this approach led to a 
significant increase of the contrast through subtraction of superficial signal components and 
therefore to an improved localization of the fluorescent source. This technique is simple to 
implement and highly relevant for studies using non-invasive NIRF imaging. 
While we focused this article on showing the usefulness of the presented surface-stripping 
approach in the particular case of cerebral ischemia in the murine brain, the results of the 
phantom study [Fig. 2] indicate that this technique is not restricted to cerebral target sites. The 
demonstrated subtraction algorithm could also be helpful when applied in other experimental 
settings, where the signal of interest clearly lies in deeper tissues, e.g. the kidney. 
The advantage of using a histogram equalization to determine β is that it is independent of 
modulations in the set-up such as changes of the excitation light intensity. However, future 
studies might show that the β value is stable for a certain set-up and a certain type of object. 
A major limitation is that the presented subtraction algorithm reduces not only the 
interfering fluorescence signals from superficial structures, but inevitably also the target 
signal. A fluorescent source of interest in a superficial layer like e.g. in a tumor model, where 
tumor cells may grow from the brain into the scalp, would be removed or at least strongly 
attenuated by the ‘surface-stripping’ approach. However, in future a wavelength shorter than 
633 nm could be applied and might allow taking advantage of a lower penetration of the 
excitation photons and hence confining excitation of fluorochromes to superficial layers. 
In an in vivo animal model, fluorescence can originate also from structures not of interest. 
This can be caused by portions of the fluorochrome circulating in the vasculature. For 
example the residual fluorescence signal from the sinus junction in the depth-weighted image 
[Fig. 3(b)] likely stems from a deep lying vessel and is thus a source of background 
fluorescence from deeper layers. 
Here, we used an epi-illumination imaging system and this geometry does not allow for 
quantification of fluorophore concentration in thick diffuse media. Even when using the 
‘surface-stripping’ technique proposed in this article, only relative changes in fluorescence 
can be obtained. Therefore, we cannot quantify how deep ‘superficial’ really is and to which 
extent the subtraction method cuts off also the signal of interest. Modeling tissue optics would 
help evaluating the usefulness and limitations of the presented subtraction algorithm. 
Nevertheless, the method could be possibly applied to tomographic approaches, using only the 
subtraction images for 3D image reconstruction. Other investigators dealing with fluorescence 
background signals in the blood system of mice have improved accuracy of quantitation by 
subtracting a constant [22,23] or a distance-dependent average [24] background fluorescence 
signal from the data before tomographic reconstruction. In contrast, our adaptive subtraction 
algorithm reduces especially superficial fluorescent background sources, depending on their 
anatomical position. This might further improve image quality and quantification accuracy 
when applied to optical tomography. Regarding the use of more than one wavelength in 
optical tomography, promising results have been presented recently by applying multi-spectral 
excitation and detection [25]. 
In conclusion, our data demonstrate that using the ‘non-invasive surface-stripping’ 
algorithm improves the visualization of fluorescent sources in deep tissue layers despite high 
background signals from superficial sources. Notably, the technique can reveal fluorescent 
sources which would have escaped conventional NIRF imaging. 
Acknowledgements 
Supported by the European Union's Seventh Framework Programme (FP7/2008-2013) under 
grant agreements n° 201024 and n° 202213 (European Stroke Network), and the German 
Ministry for Health and Education, the Zukunftsfonds Berlin  and the European Regional 
Development Fund (ERDF) of the EU. Furthermore we would like to thank Hans-Hermann 
#129204 - $15.00 USD Received 1 Jun 2010; revised 24 Jun 2010; accepted 2 Jul 2010; published 14 Jul 2010
(C) 2010 OSA 2 August 2010 / Vol. 1,  No. 1 / BIOMEDICAL OPTICS EXPRESS  104Schrenk and Eva Frei (German Cancer Research Center Heidelberg, Germany) for providing 
us with Cy5.5-HSA. 
#129204 - $15.00 USD Received 1 Jun 2010; revised 24 Jun 2010; accepted 2 Jul 2010; published 14 Jul 2010
(C) 2010 OSA 2 August 2010 / Vol. 1,  No. 1 / BIOMEDICAL OPTICS EXPRESS  105